Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Expanding the Applied Biosystems portfolio with the latest generation of innovative, mid-throughput genetic analyzers
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
A simple blood test detects over 30 types of cancers
TruPharma has commenced commercial marketing of Sage's approved generic cartridge product
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
With ValGenesis VLMS, change control driven validation activities are reduced from weeks to mere hours, and the company gains faster access to detailed metrics that help reduce costs and cycle time
The partnership will help digitize and automate existing tasks traditionally managed on paper, significantly reducing costs and lead times while increasing compliance
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
Subscribe To Our Newsletter & Stay Updated
